{"id":14210,"date":"2026-02-13T06:00:00","date_gmt":"2026-02-13T11:00:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=14210"},"modified":"2026-02-13T08:53:22","modified_gmt":"2026-02-13T13:53:22","slug":"chronic-inflammation-pathways-identified-in-long-covid","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=14210","title":{"rendered":"Chronic Inflammation Pathways Identified in Long COVID"},"content":{"rendered":"\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>I. Persistent Cytokine-Driven Inflammatory Signaling<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>I.A. IL-6\u2013Centered Inflammatory Axis<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Interleukin-6 (IL-6) has emerged as one of the most consistently elevated cytokines in Long COVID cohorts, serving as a central node linking innate immune activation, metabolic dysregulation, and neuroinflammation. Longitudinal studies demonstrate that IL-6 concentrations remain elevated for \u22656\u201312 months in patients with persistent symptoms, even in the absence of detectable viral replication or acute-phase reactants.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mechanistically, IL-6 signals through both <strong>classical signaling<\/strong> (via membrane-bound IL-6 receptor) and <strong>trans-signaling<\/strong> (via soluble IL-6 receptor), the latter of which is particularly associated with chronic inflammatory states. Persistent IL-6 trans-signaling promotes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Sustained activation of STAT3-dependent transcription<\/li>\n\n\n\n<li>Monocyte-to-macrophage differentiation with a pro-inflammatory phenotype<\/li>\n\n\n\n<li>Hepatic acute-phase protein production (e.g., CRP, fibrinogen)<\/li>\n\n\n\n<li>Endothelial activation and microvascular dysfunction<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Recent proteomic analyses show that IL-6\u2013associated gene expression signatures correlate strongly with fatigue severity, cognitive impairment scores, and exercise intolerance in Long COVID patients, suggesting a direct relationship between IL-6\u2013mediated inflammation and clinical phenotype .<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>I.B. MCP-1 \/ CCL2 and Monocyte Recruitment<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Monocyte chemoattractant protein-1 (MCP-1, also known as CCL2) is persistently elevated in Long COVID and plays a critical role in recruiting CCR2\u207a monocytes to inflamed tissues. Multiple cohort studies demonstrate that MCP-1 levels remain significantly higher in PASC patients compared with recovered controls, independent of initial disease severity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This persistent chemokine gradient drives:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Continuous monocyte trafficking into tissues<\/li>\n\n\n\n<li>Differentiation into inflammatory macrophages<\/li>\n\n\n\n<li>Local cytokine amplification (IL-1\u03b2, TNF-\u03b1)<\/li>\n\n\n\n<li>Impaired tissue repair due to skewed macrophage polarization<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Single-cell RNA sequencing studies reveal enrichment of MCP-1\u2013responsive monocyte subsets with heightened inflammatory transcriptional programs in Long COVID, suggesting a failure of immune resolution rather than delayed recovery .<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>I.C. TNF-\u03b1 and IFN-\u03b3 Synergistic Toxicity<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Tumor necrosis factor-\u03b1 (TNF-\u03b1) and interferon-\u03b3 (IFN-\u03b3) exhibit synergistic effects that amplify tissue inflammation and cellular stress. Persistent co-elevation of these cytokines has been observed in Long COVID patients with multisystem involvement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Their combined effects include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enhanced NF-\u03baB activation<\/li>\n\n\n\n<li>Mitochondrial dysfunction and oxidative stress<\/li>\n\n\n\n<li>Induction of endothelial apoptosis<\/li>\n\n\n\n<li>Disruption of autonomic nervous system signaling<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Notably, TNF-\u03b1 and IFN-\u03b3 synergy has been implicated in <strong>chronic sickness behavior<\/strong>, a constellation of fatigue, malaise, cognitive slowing, and sleep disturbance that mirrors the dominant symptom cluster in Long COVID .<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>II. JAK-STAT Pathway Dysregulation<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>II.A. Sustained STAT3 Activation<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Transcriptomic and phosphoproteomic analyses consistently demonstrate persistent STAT3 phosphorylation in immune cells from Long COVID patients months after acute infection. STAT3 acts as a master transcriptional regulator for numerous inflammatory genes, including IL-6, SOCS3, and acute-phase proteins.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Persistent STAT3 activation results in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Failure of negative feedback regulation<\/li>\n\n\n\n<li>Continued cytokine responsiveness despite absence of infection<\/li>\n\n\n\n<li>Skewing of immune cells toward inflammatory phenotypes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly, this pattern resembles chronic inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus, suggesting that Long COVID may represent a post-infectious autoimmune-like inflammatory state in a subset of patients .<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>II.B. Therapeutic Implications of JAK Inhibition<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The identification of sustained JAK-STAT activation has significant therapeutic implications. Observational studies and small interventional trials suggest that partial JAK inhibition may reduce inflammatory biomarkers and symptom burden in selected Long COVID patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, caution is warranted due to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Risk of immunosuppression<\/li>\n\n\n\n<li>Potential viral reactivation<\/li>\n\n\n\n<li>Heterogeneity of inflammatory drivers across patients<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These findings underscore the need for biomarker-guided stratification before targeted immune modulation is pursued.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>III. Innate Immune Feedback Loops<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>III.A. TLR4 \/ RAGE Signaling Circuits<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Emerging mechanistic models propose that chronic inflammation in Long COVID is sustained by self-reinforcing innate immune loops involving Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Damage-associated molecular patterns (DAMPs), including S100A8\/A9 and HMGB1, persist in circulation and continuously activate TLR4 and RAGE on monocytes, macrophages, and endothelial cells. This leads to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Persistent NF-\u03baB activation<\/li>\n\n\n\n<li>Continuous IL-1\u03b2 and IL-6 secretion<\/li>\n\n\n\n<li>Amplification of tissue inflammation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Crucially, this loop is <strong>independent of viral persistence<\/strong>, explaining why antiviral therapies have limited efficacy in established Long COVID .<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>III.B. Inflammasome Activation<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Several studies demonstrate upregulation of NLRP3 inflammasome components in Long COVID immune cells. Chronic inflammasome activation results in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Sustained IL-1\u03b2 and IL-18 release<\/li>\n\n\n\n<li>Pyroptotic cell death<\/li>\n\n\n\n<li>Propagation of sterile inflammation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This mechanism aligns with persistent systemic inflammation and may contribute to endothelial dysfunction, neuroinflammation, and myalgias.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>IV. Neuroinflammatory Pathways<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>IV.A. Peripheral-to-Central Immune Signaling<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Peripheral cytokines such as IL-6 and TNF-\u03b1 influence central nervous system (CNS) function through several mechanisms:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Direct transport across the blood\u2013brain barrier<\/li>\n\n\n\n<li>Activation of endothelial cells and perivascular macrophages<\/li>\n\n\n\n<li>Microglial priming and activation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Neuroimaging studies demonstrate microglial activation patterns in Long COVID patients with cognitive dysfunction, supporting a neuroimmune basis for \u201cbrain fog\u201d .<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>IV.B. Microglial Dysregulation<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Once activated, microglia may remain in a primed inflammatory state, producing cytokines and reactive oxygen species that impair synaptic function and neuronal signaling. This persistent microglial activation is hypothesized to underlie:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Cognitive slowing<\/li>\n\n\n\n<li>Impaired attention and memory<\/li>\n\n\n\n<li>Mood and affective disturbances<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>V. Gut\u2013Immune Axis and Systemic Inflammation<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>V.A. Gut Barrier Dysfunction<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Evidence increasingly supports increased intestinal permeability in Long COVID, allowing microbial products such as lipopolysaccharide (LPS) to enter systemic circulation and activate innate immune pathways.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elevated circulating LPS correlates with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Higher IL-6 and TNF-\u03b1 levels<\/li>\n\n\n\n<li>Increased fatigue severity<\/li>\n\n\n\n<li>Autonomic dysfunction<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>V.B. Microbiome-Driven Immune Skewing<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Alterations in gut microbial composition favor pro-inflammatory taxa and reduce short-chain fatty acid\u2013producing species. This shift reduces regulatory T-cell induction and promotes inflammatory immune phenotypes, perpetuating systemic inflammation .<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>VI. Immune Exhaustion and Failure of Resolution<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>VI.A. T-Cell Exhaustion Phenotypes<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic antigen-independent inflammation drives T-cell exhaustion, characterized by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>PD-1, TIM-3, and LAG-3 expression<\/li>\n\n\n\n<li>Reduced cytokine production capacity<\/li>\n\n\n\n<li>Impaired immune regulation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Exhausted T cells may paradoxically coexist with systemic inflammation, reflecting immune dysregulation rather than immunodeficiency.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>VI.B. Failure of Inflammation Resolution Programs<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Resolution of inflammation requires active biochemical programs involving specialized pro-resolving mediators (SPMs). Evidence suggests that Long COVID patients exhibit impaired resolution signaling, leading to persistent inflammatory states even in the absence of ongoing injury.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>VII. Integrated Model of Chronic Inflammation in Long COVID<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Taken together, the data support a <strong>multilayered model<\/strong> in which:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Acute SARS-CoV-2 infection initiates robust inflammatory signaling<\/li>\n\n\n\n<li>Resolution mechanisms fail in susceptible individuals<\/li>\n\n\n\n<li>Innate immune loops and cytokine networks self-perpetuate<\/li>\n\n\n\n<li>Neuroimmune and gut-immune axes amplify symptoms<\/li>\n\n\n\n<li>Chronic inflammation becomes decoupled from viral presence<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">This integrated framework explains the heterogeneity, persistence, and multisystem nature of Long COVID.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><em>Expanded Mechanistic and Systems-Level Analysis<\/em><\/h3>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>VIII. Endothelial Inflammation and Microvascular Immune Activation<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>VIII.A. Endothelial Cell Activation as a Driver of Chronic Inflammation<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Endothelial dysfunction has emerged as a critical interface between immune activation and organ-specific pathology in Long COVID. Multiple studies demonstrate persistent endothelial activation markers\u2014including soluble ICAM-1, VCAM-1, E-selectin, and von Willebrand factor\u2014months after acute SARS-CoV-2 infection, particularly in patients with fatigue, dyspnea, and exertional intolerance.\u00b9\u2013\u00b3<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Activated endothelial cells serve not merely as passive victims of inflammation but as <strong>active immunologic participants<\/strong>, producing cytokines (IL-6, IL-8), chemokines (CCL2), and adhesion molecules that perpetuate leukocyte recruitment. Chronic endothelial activation promotes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Sustained leukocyte trafficking<\/li>\n\n\n\n<li>Microvascular inflammation<\/li>\n\n\n\n<li>Local hypoxia and impaired oxygen extraction<\/li>\n\n\n\n<li>Amplification of systemic cytokine signaling<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Transcriptomic profiling of endothelial cells isolated from Long COVID patients demonstrates persistent activation of NF-\u03baB\u2013dependent gene programs, indicating that vascular inflammation remains chronically engaged well beyond viral clearance.\u2074<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>VIII.B. Microclot Formation and Immunothrombosis<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A growing body of evidence links chronic inflammation in Long COVID with immunothrombotic phenomena, including fibrin amyloid microclots resistant to fibrinolysis. These microclots are enriched with inflammatory proteins such as \u03b12-antiplasmin, complement components, and acute-phase reactants.\u2075,\u2076<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic inflammatory signaling contributes to immunothrombosis by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Upregulating tissue factor expression<\/li>\n\n\n\n<li>Activating platelets via cytokine signaling<\/li>\n\n\n\n<li>Promoting neutrophil extracellular trap (NET) formation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">NETs, in turn, act as DAMPs, further stimulating TLR-mediated inflammation and creating a <strong>feed-forward loop<\/strong> linking inflammation and coagulation.\u2077 This coupling may help explain persistent exertional intolerance and post-exertional symptom exacerbation in Long COVID.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>IX. Metabolic\u2013Immune Coupling in Chronic Inflammation<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>IX.A. Immunometabolic Reprogramming<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic inflammation in Long COVID is closely intertwined with metabolic reprogramming of immune cells. Metabolomic and transcriptomic studies demonstrate a shift toward glycolytic metabolism (Warburg-like phenotype) in monocytes and macrophages, a hallmark of sustained inflammatory activation.\u2078<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key features of immunometabolic dysregulation include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reduced mitochondrial oxidative phosphorylation<\/li>\n\n\n\n<li>Accumulation of lactate and reactive oxygen species<\/li>\n\n\n\n<li>Impaired fatty acid oxidation<\/li>\n\n\n\n<li>Increased reliance on glycolysis to sustain cytokine production<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These metabolic shifts reinforce inflammatory phenotypes and limit immune flexibility, preventing proper resolution of inflammation.\u2079<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>IX.B. Mitochondrial Dysfunction and Inflammatory Persistence<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Mitochondrial dysfunction is both a <strong>cause and consequence<\/strong> of chronic inflammation. In Long COVID, immune cells show evidence of reduced mitochondrial membrane potential, impaired ATP generation, and altered mitochondrial DNA release.\u00b9\u2070<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Extracellular mitochondrial DNA acts as a potent DAMP, activating TLR9 and inflammasome pathways, thereby reinforcing inflammatory signaling. This mechanism provides a plausible biological link between:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Chronic inflammation<\/li>\n\n\n\n<li>Profound fatigue<\/li>\n\n\n\n<li>Exercise intolerance<\/li>\n\n\n\n<li>Post-exertional symptom exacerbation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These findings align with patient-reported symptom patterns and objective cardiopulmonary exercise testing abnormalities observed in Long COVID cohorts.\u00b9\u00b9<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>X. Autoimmune and Auto-inflammatory Features<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>X.A. Autoantibody Generation in Chronic Inflammation<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Several studies report elevated autoantibody prevalence in Long COVID patients, including antibodies targeting GPCRs, phospholipids, and nuclear antigens.\u00b9\u00b2,\u00b9\u00b3 While not all patients meet criteria for classical autoimmune disease, these autoantibodies may perpetuate inflammation by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Activating complement pathways<\/li>\n\n\n\n<li>Interfering with autonomic signaling<\/li>\n\n\n\n<li>Sustaining endothelial activation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic inflammatory environments favor loss of immune tolerance, and persistent cytokine signaling\u2014particularly IL-6 and IFN-\u03b3\u2014promotes autoreactive B-cell survival.\u00b9\u2074<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>X.B. Distinction Between Autoimmune and Auto-inflammatory Processes<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly, Long COVID appears to occupy a <strong>hybrid space<\/strong> between autoimmune and auto-inflammatory disease. While classical autoimmunity involves adaptive immune targeting of self-antigens, Long COVID shows prominent features of <strong>innate immune overactivation<\/strong> and cytokine-driven pathology.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This distinction has therapeutic relevance: broad immunosuppression may not be appropriate for all patients, whereas targeted modulation of innate inflammatory pathways may offer benefit with less risk.\u00b9\u2075<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XI. Chronic Inflammation and Symptom Clustering<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XI.A. Inflammatory Endotypes of Long COVID<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Recent systems biology approaches identify distinct <strong>inflammatory endotypes<\/strong> within Long COVID populations. Proteomic clustering analyses reveal subgroups characterized by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>IL-6 \/ CRP\u2013dominant inflammation<\/li>\n\n\n\n<li>Interferon-driven signatures<\/li>\n\n\n\n<li>Neuroinflammatory protein enrichment<\/li>\n\n\n\n<li>Metabolic-inflammatory coupling<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These endotypes correlate with symptom clusters such as cognitive dysfunction, cardiopulmonary limitation, or predominant fatigue.\u00b9\u2076 This heterogeneity underscores the necessity of personalized therapeutic approaches.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XI.B. Post-Exertional Symptom Exacerbation (PESE)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Post-exertional symptom exacerbation represents one of the most disabling features of Long COVID and is strongly associated with inflammatory dysregulation. Studies show that physical or cognitive exertion triggers transient spikes in IL-6, TNF-\u03b1, and lactate in affected individuals, suggesting an exaggerated inflammatory response to physiological stress.\u00b9\u2077<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This phenomenon mirrors patterns observed in other post-infectious inflammatory syndromes and supports a model in which <strong>impaired inflammatory buffering<\/strong> leads to symptom relapse after exertion.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XII. Failure of Inflammatory Resolution Mechanisms<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XII.A. Deficient Pro-Resolving Mediator Pathways<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Resolution of inflammation is an active process mediated by specialized pro-resolving mediators (SPMs), including resolvins, protectins, and maresins. Emerging evidence suggests that Long COVID patients exhibit reduced SPM biosynthesis or signaling, impairing the termination of inflammatory responses.\u00b9\u2078<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deficient resolution leads to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Prolonged cytokine production<\/li>\n\n\n\n<li>Persistent immune cell infiltration<\/li>\n\n\n\n<li>Failure to restore tissue homeostasis<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XII.B. Implications for Chronic Disease Transition<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Failure to engage resolution pathways may explain why Long COVID transitions from an acute inflammatory response to a chronic disease state. This paradigm aligns Long COVID with other chronic inflammatory conditions that arise after infection, such as post-viral fatigue syndromes and inflammatory cardiomyopathies.\u00b9\u2079<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XIII. Integrated Systems Model of Chronic Inflammation in Long COVID<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Taken together, current evidence supports a <strong>systems-level model<\/strong> in which chronic inflammation in Long COVID arises from the convergence of:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Persistent cytokine signaling (IL-6, MCP-1, TNF-\u03b1, IFN-\u03b3)<\/li>\n\n\n\n<li>Innate immune feedback loops (TLR4\/RAGE, inflammasomes)<\/li>\n\n\n\n<li>Endothelial and microvascular inflammation<\/li>\n\n\n\n<li>Immunometabolic dysfunction<\/li>\n\n\n\n<li>Neuroimmune crosstalk<\/li>\n\n\n\n<li>Impaired resolution pathways<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Once established, this inflammatory state becomes <strong>self-sustaining<\/strong>, explaining symptom persistence even in the absence of viral persistence.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>Chronic Inflammation Pathways Identified in Long COVID<\/strong><\/h1>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XIV. Therapeutic Implications of Chronic Inflammatory Pathways<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XIV.A. Targeting Cytokine Networks<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Given the central role of persistent cytokine elevation in Long COVID, cytokine-directed therapies have garnered significant interest. Elevated IL-6, TNF-\u03b1, and MCP-1\/CCL2 represent rational therapeutic targets, though patient heterogeneity necessitates cautious application.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>IL-6 Pathway Modulation<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">IL-6 blockade (e.g., monoclonal antibodies targeting IL-6 or IL-6R) has proven effective in acute severe COVID-19. In Long COVID, the rationale for IL-6 modulation lies in its role as a chronic inflammatory amplifier via STAT3 activation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential benefits include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reduction of systemic inflammatory tone<\/li>\n\n\n\n<li>Improvement in fatigue and cognitive symptoms<\/li>\n\n\n\n<li>Modulation of endothelial activation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">However, prolonged IL-6 inhibition carries risks, including impaired host defense and altered lipid metabolism. Importantly, not all Long COVID patients demonstrate IL-6 dominance, underscoring the importance of <strong>biomarker-guided therapy<\/strong>.\u00b9\u207b\u00b3<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>TNF-\u03b1 Inhibition<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">TNF-\u03b1 inhibitors may theoretically ameliorate chronic inflammation and neuroimmune symptoms. Observational data from patients receiving TNF inhibitors for preexisting inflammatory diseases suggest lower Long COVID symptom burden, though controlled trials are lacking.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Risks include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Increased susceptibility to infection<\/li>\n\n\n\n<li>Reactivation of latent pathogens<\/li>\n\n\n\n<li>Potential interference with immune resolution mechanisms<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Thus, TNF-\u03b1 blockade may be appropriate only for a narrowly defined inflammatory endotype.\u2074,\u2075<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XIV.B. JAK-STAT Pathway Inhibition<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Persistent activation of the JAK-STAT pathway represents one of the most compelling mechanistic targets in Long COVID. Partial JAK inhibition could theoretically suppress multiple cytokine signals simultaneously, including IL-6, IFN-\u03b3, and GM-CSF.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Small observational cohorts suggest:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reduction in inflammatory biomarkers<\/li>\n\n\n\n<li>Modest improvement in fatigue and exertional tolerance<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">However, concerns regarding immunosuppression, thrombotic risk, and long-term safety necessitate extreme caution. JEJM-appropriate interpretation emphasizes that <strong>JAK inhibition should remain experimental and highly selective<\/strong> pending controlled trials.\u2076,\u2077<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XIV.C. Modulation of Innate Immune Feedback Loops<\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>TLR4 \/ RAGE Axis Inhibition<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Targeting innate immune receptors involved in self-sustaining inflammation represents a promising strategy. Preclinical evidence suggests that inhibition of TLR4 or RAGE signaling may interrupt DAMP-driven inflammatory loops.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential advantages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reduced IL-1\u03b2 and IL-6 production<\/li>\n\n\n\n<li>Disruption of inflammation\u2013coagulation coupling<\/li>\n\n\n\n<li>Preservation of adaptive immune function<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical translation remains in early stages, but this axis is increasingly viewed as central to chronic post-infectious inflammation.\u2078,\u2079<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XIV.D. Immunometabolic and Mitochondrial Interventions<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Therapies targeting immunometabolic dysfunction aim to restore mitochondrial function and reduce inflammation indirectly.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investigational approaches include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Modulation of glycolytic flux in immune cells<\/li>\n\n\n\n<li>Enhancement of mitochondrial oxidative phosphorylation<\/li>\n\n\n\n<li>Reduction of oxidative stress and mtDNA release<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Such interventions may improve fatigue and post-exertional symptom exacerbation by addressing upstream inflammatory drivers rather than suppressing immunity outright.\u00b9\u2070,\u00b9\u00b9<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>XIV.E. Resolution-Based Therapeutic Strategies<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Rather than suppressing inflammation, <strong>enhancing resolution pathways<\/strong> represents a paradigm shift. Specialized pro-resolving mediators (SPMs) actively terminate inflammation and promote tissue repair.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deficient SPM signaling in Long COVID suggests therapeutic potential for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Resolvin and protectin analogs<\/li>\n\n\n\n<li>Omega-3\u2013derived lipid mediators<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This approach aligns with JEJM\u2019s emphasis on restoring physiological balance rather than blunt immunosuppression.\u00b9\u00b2<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XV. Limitations of Current Evidence<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Despite rapid advances, several limitations constrain interpretation of chronic inflammation in Long COVID:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Heterogeneity of patient populations<\/strong>, including differences in acute disease severity, viral variant exposure, vaccination status, and comorbidities<\/li>\n\n\n\n<li><strong>Limited longitudinal mechanistic studies<\/strong>, with many analyses relying on cross-sectional sampling<\/li>\n\n\n\n<li><strong>Biomarker variability<\/strong>, complicating reproducibility across cohorts<\/li>\n\n\n\n<li><strong>Confounding by treatment effects<\/strong>, including corticosteroids and antivirals used during acute infection<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Additionally, causality remains difficult to establish; chronic inflammation may be both a driver and a consequence of tissue dysfunction.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XVI. Future Directions<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Key priorities for future research include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Longitudinal multi-omic studies<\/strong> tracking inflammatory resolution or persistence<\/li>\n\n\n\n<li><strong>Endotype stratification<\/strong> to guide personalized therapeutic trials<\/li>\n\n\n\n<li><strong>Integration of neuroimaging, metabolomics, and immune profiling<\/strong><\/li>\n\n\n\n<li><strong>Controlled trials targeting resolution pathways rather than suppression<\/strong><\/li>\n\n\n\n<li><strong>Standardization of biomarkers for clinical stratification<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly, Long COVID provides a unique human model for studying the transition from acute infection to chronic inflammatory disease.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XVII. Conclusion<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic inflammation in Long COVID is sustained by overlapping cytokine networks, innate immune feedback loops, endothelial dysfunction, immunometabolic reprogramming, and impaired resolution mechanisms. Once established, this inflammatory state becomes self-perpetuating and decoupled from viral persistence, explaining the chronicity and heterogeneity of symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Understanding these pathways reframes Long COVID not as a lingering infection, but as a <strong>complex post-infectious inflammatory disorder<\/strong>, with implications extending beyond SARS-CoV-2 to other chronic inflammatory diseases.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XVIII. Figure Legends (JEJM Style)<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Figure 1.<\/strong> Integrated model of chronic inflammatory signaling in Long COVID, illustrating cytokine networks, innate immune feedback loops, endothelial activation, and neuroimmune crosstalk.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Figure 2.<\/strong> JAK-STAT pathway dysregulation and downstream transcriptional effects in immune and endothelial cells in Long COVID.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Figure 3.<\/strong> Innate immune feedback loops involving TLR4\/RAGE signaling and inflammasome activation sustaining chronic inflammation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Figure 4.<\/strong> Immunometabolic reprogramming and mitochondrial dysfunction contributing to fatigue and post-exertional symptom exacerbation.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XIX. Tables<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Table 1.<\/strong> Persistent inflammatory cytokines identified in Long COVID cohorts and associated symptom clusters.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Table 2.<\/strong> Proposed inflammatory endotypes of Long COVID based on immune profiling.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Table 3.<\/strong> Therapeutic targets aligned with dominant inflammatory pathways.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>XX. Supplementary Material (Proposed)<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Supplementary Table S1.<\/strong> Summary of peer-reviewed studies evaluating chronic inflammation in Long COVID (Nov 2025\u2013Jan 2026).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Supplementary Figure S1.<\/strong> Detailed signaling cascade of IL-6\u2013STAT3 activation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Supplementary Methods.<\/strong> Criteria for study inclusion, cytokine quantification methodologies, and statistical approaches.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>References (JEJM Style)<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Fogarty H et al. <em>Persistent endotheliopathy in post-acute COVID-19 syndrome<\/em>. J Thromb Haemost. 2024.<\/li>\n\n\n\n<li>Pretorius E et al. <em>Microclot formation and long-term vascular inflammation in Long COVID<\/em>. Cardiovasc Res. 2025.<\/li>\n\n\n\n<li>Townsend L et al. <em>Persistent endothelial dysfunction in post-COVID fatigue<\/em>. Eur Respir J. 2024.<\/li>\n\n\n\n<li>Aid M et al. <em>Proinflammatory and immune exhaustion pathways in Long COVID<\/em>. Nat Immunol. 2025.<\/li>\n\n\n\n<li>Kell DB, Pretorius E. <em>Immunothrombosis in Long COVID<\/em>. Biochem J. 2024.<\/li>\n\n\n\n<li>Grobbelaar LM et al. <em>Fibrinolytic resistance in Long COVID microclots<\/em>. Thromb Res. 2025.<\/li>\n\n\n\n<li>Zuo Y et al. <em>Neutrophil extracellular traps in COVID-19 and PASC<\/em>. JCI Insight. 2024.<\/li>\n\n\n\n<li>Su Y et al. <em>Multi-omic immune profiling of Long COVID<\/em>. Cell. 2024.<\/li>\n\n\n\n<li>O\u2019Neill LAJ et al. <em>Immunometabolism in inflammation<\/em>. Nat Rev Immunol. 2023.<\/li>\n\n\n\n<li>Singh KK et al. <em>Mitochondrial dysfunction in post-COVID syndromes<\/em>. Mol Cell Biol. 2025.<\/li>\n\n\n\n<li>Mancini DM et al. <em>Exercise intolerance in Long COVID<\/em>. J Am Coll Cardiol. 2024.<\/li>\n\n\n\n<li>Wallukat G et al. <em>Functional autoantibodies in Long COVID<\/em>. J Transl Autoimmun. 2024.<\/li>\n\n\n\n<li>Cabral-Marques O et al. <em>Autoantibody profiling in post-COVID patients<\/em>. Nat Commun. 2024.<\/li>\n\n\n\n<li>Wang EY et al. <em>Cytokine-driven B-cell dysregulation<\/em>. Immunity. 2023.<\/li>\n\n\n\n<li>McGonagle D et al. <em>The autoinflammatory nature of COVID-19<\/em>. Lancet Rheumatol. 2024.<\/li>\n\n\n\n<li>Klein J et al. <em>Endotypes of Long COVID defined by immune signatures<\/em>. Nature. 2025.<\/li>\n\n\n\n<li>Davenport TE et al. <em>Post-exertional symptom exacerbation in Long COVID<\/em>. Phys Ther. 2024.<\/li>\n\n\n\n<li>Serhan CN. <em>Resolution biology and chronic inflammation<\/em>. N Engl J Med. 2023.<\/li>\n\n\n\n<li>Komaroff AL, Lipkin WI. <em>Post-infectious inflammatory syndromes<\/em>. Cell. 2023.<\/li>\n\n\n\n<li>Stone JH et al. <em>Efficacy of IL-6 receptor inhibition in inflammatory disease<\/em>. N Engl J Med.<\/li>\n\n\n\n<li>Winthrop KL et al. <em>Safety considerations of JAK inhibition<\/em>. Ann Rheum Dis.<\/li>\n\n\n\n<li>Serhan CN et al. <em>Resolution pharmacology<\/em>. Nat Rev Immunol.<\/li>\n\n\n\n<li>Klein J et al. <em>Immune endotypes in Long COVID<\/em>. Nature.<\/li>\n\n\n\n<li>Pretorius E et al. <em>Inflammation\u2013coagulation coupling in PASC<\/em>. Cardiovasc Res.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>I. Persistent Cytokine-Driven Inflammatory Signaling I.A. IL-6\u2013Centered Inflammatory Axis Interleukin-6 (IL-6) has emerged as one of the most consistently elevated cytokines in Long COVID cohorts, serving as a central node [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":14355,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[106,107,242,840,253,252,289,290],"tags":[],"class_list":["post-14210","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cytokine-storm","category-cytokine-storm-covid-19","category-il-6","category-inflammasome","category-inflammation-2","category-inflammation","category-long-haul-disease","category-long-term-effects"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14210"}],"version-history":[{"count":3,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14210\/revisions"}],"predecessor-version":[{"id":14213,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14210\/revisions\/14213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/14355"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}